Short Interest in Krystal Biotech, Inc. (NASDAQ:KRYS) Declines By 8.9%

Krystal Biotech, Inc. (NASDAQ:KRYS) was the target of a significant decrease in short interest in the month of December. As of December 31st, there was short interest totalling 3,370,000 shares, a decrease of 8.9% from the December 15th total of 3,700,000 shares. Based on an average daily volume of 247,300 shares, the short-interest ratio is presently 13.6 days.

Krystal Biotech Price Performance

Shares of Krystal Biotech stock opened at $148.39 on Monday. The stock has a market cap of $4.27 billion, a price-to-earnings ratio of 83.84 and a beta of 0.85. The firm’s 50-day moving average is $170.98 and its two-hundred day moving average is $182.18. Krystal Biotech has a 1 year low of $107.50 and a 1 year high of $219.34.

Krystal Biotech (NASDAQ:KRYS) last issued its quarterly earnings data on Monday, November 4th. The company reported $0.91 earnings per share for the quarter, topping analysts’ consensus estimates of $0.84 by $0.07. The firm had revenue of $83.84 million during the quarter, compared to analysts’ expectations of $82.94 million. Krystal Biotech had a return on equity of 7.54% and a net margin of 21.68%. The firm’s quarterly revenue was up 879.9% on a year-over-year basis. During the same period in the prior year, the business posted ($0.67) EPS. On average, equities analysts expect that Krystal Biotech will post 3.03 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on the company. Citigroup boosted their price objective on Krystal Biotech from $204.00 to $206.00 and gave the company a “neutral” rating in a report on Tuesday, November 5th. Chardan Capital reissued a “buy” rating and set a $212.00 target price on shares of Krystal Biotech in a research note on Wednesday, December 18th. Finally, HC Wainwright restated a “buy” rating and issued a $221.00 target price on shares of Krystal Biotech in a research note on Wednesday, December 18th. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Buy” and an average target price of $206.67.

Insider Buying and Selling at Krystal Biotech

In related news, insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction dated Friday, December 13th. The shares were sold at an average price of $164.78, for a total transaction of $4,119,500.00. Following the completion of the transaction, the insider now directly owns 1,475,882 shares of the company’s stock, valued at approximately $243,195,835.96. The trade was a 1.67 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 14.10% of the company’s stock.

Hedge Funds Weigh In On Krystal Biotech

Several hedge funds have recently modified their holdings of the stock. Dimensional Fund Advisors LP grew its stake in Krystal Biotech by 1.3% during the 2nd quarter. Dimensional Fund Advisors LP now owns 580,452 shares of the company’s stock valued at $106,593,000 after purchasing an additional 7,537 shares during the last quarter. Mutual of America Capital Management LLC lifted its holdings in shares of Krystal Biotech by 9.2% during the second quarter. Mutual of America Capital Management LLC now owns 37,324 shares of the company’s stock worth $6,854,000 after purchasing an additional 3,135 shares during the period. Amalgamated Bank boosted its position in Krystal Biotech by 937.9% in the second quarter. Amalgamated Bank now owns 7,577 shares of the company’s stock valued at $1,391,000 after buying an additional 6,847 shares during the last quarter. Vanguard Personalized Indexing Management LLC acquired a new position in Krystal Biotech in the 2nd quarter worth approximately $252,000. Finally, Sei Investments Co. raised its position in Krystal Biotech by 18.9% during the 2nd quarter. Sei Investments Co. now owns 40,115 shares of the company’s stock worth $7,367,000 after buying an additional 6,363 shares during the last quarter. Institutional investors and hedge funds own 86.29% of the company’s stock.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).